The Circulating Cell-Free Tumor DNA Market is estimated to witness high growth owing to increasing demand for non-invasive diagnostic techniques. Circulating cell-free tumor DNA analysis is a non-invasive test that helps detect tumor-derived DNA fragments in the blood of cancer patients. This technique aids in early cancer detection, prognosis, recurrence monitoring, and treatment response assessment without the need for invasive tissue biopsies.
Circulating cell-free tumor DNA refers to fragmented DNA released by tumor cells into the bloodstream. Analysis of circulating tumor DNA helps gain insights into tumor mutations, evolution, and dynamics during treatment. It provides a simple and quick way to monitor cancer progression or recurrence as compared to repeated tumor biopsies. This market is gaining popularity due to various advantages of circulating tumor DNA analysis such as detection of minimal residual disease, guidance in targeted therapy selection, and treatment monitoring in a cost-effective manner.
The increasing demand for non-invasive diagnostic techniques is a major trend fueling market growth. Circulating tumor DNA analysis offers a non-invasive alternative to tissue biopsies. It helps in cancer genomic profiling without requiring an invasive biopsy procedure. Moreover, technological advancements are leading to the development of highly sensitive diagnostic platforms to analyze low levels of circulating tumor DNA. Other trends include growing applications of liquid biopsies in early cancer detection and research on circulating tumor DNA to develop personalized treatment regimens. The integration of circulating tumor DNA analysis with cancer genomics is also expanding clinical utility.
The Global Circulating Cell-free Tumor DNA Market Size is expected to witness high growth, exhibiting CAGR of 22% over the forecast period, due to increasing cancer prevalence worldwide. North America dominated the market in 2023 due to supportive reimbursement policies and advanced healthcare infrastructure in the region. Europe is anticipated to register fastest growth during the forecast period.
Read More
https://healthcarelatesteditionnews.blogspot.com/2023/11/circulating-cell-free-tumor-dna-market.html
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian